ClinicalTrials.gg
Active, not recruitingNCT07936318Effect of TherUpdated Nov 13, 2026

Effect of Therapeutic Storybook Series on Anxiety in Children Undergoing Chemotherapy

An interventional study of therapeutic Storybook Series ("Adam's Journey in the Kingdom of the Body" in Chemotherapy-Related Anxiety and Pediatric Cancer, sponsored by Asmaa Rashad. Active, not recruiting at 1 site in Egypt. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Asmaa Rashad · Not applicable, Interventional, and Supportive care

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
6 Years to 10 Years
Sex
All
01

Study summary

Study Purpose: This study evaluates how a structured series of four illustrated therapeutic storybooks ("Adam's Journey in the Kingdom of the Body") helps reduce anxiety and build coping skills in children aged 6 to 10 years who are undergoing chemotherapy. How It Works: Children in the intervention group participate in four interactive storytelling sessions (20-30 minutes each, delivered twice weekly over two weeks) alongside their routine hospital care. A control group receives routine hospital care alone. Key Benefits: The storybooks use gentle metaphors and post-traumatic growth principles to help children understand their treatment, process their fears of procedures or side effects, and feel more confident and supported during their hospital journey.

Read the detailed description

Background and Rationale: Childhood cancer and its primary treatment modality, chemotherapy, impose significant physical and psychological burdens, resulting in anxiety prevalence rates between 20% and 40% among pediatric patients. This distress often manifests as behavioral problems, sleep disturbances, and reduced treatment compliance. Non-pharmacological interventions such as therapeutic storytelling offer a safe, cognitive-behavioral approach to help children process fears, normalize experiences, and foster post-traumatic growth. However, there is a paucity of structured, culturally adapted multi-session storybook interventions evaluated within the Egyptian pediatric oncology context. Study Design: This is a quasi-experimental study utilizing a pretest-posttest control group design. Participants are randomly allocated into either an intervention group or a control group. Intervention Group Procedure: Children assigned to the intervention group receive a structured therapeutic storybook series titled "Adam's Journey in the Kingdom of the Body" in addition to routine hospital care. The series consists of four interconnected illustrated stories delivered by the researcher in four individual 20-to-30-minute sessions (twice weekly over a two-week period) in a quiet hospital setting. The stories incorporate three layers (adventure, parent/metaphor, and therapeutic goal) designed around psychological defense mechanisms and post-traumatic growth to guide children from fear to understanding. Control Group Procedure: Children in the control group receive routine hospital care only. Evaluations and Assessments: Baseline anxiety levels are assessed for both groups using the Hospital Anxiety Scale (HAS) one day prior to scheduled chemotherapy. Post-intervention anxiety assessments are re-administered to both groups within 24 hours following the final storytelling session. Additionally, child and parent satisfaction questionnaires are administered to evaluate the intervention experience

02

Conditions studied

  • Chemotherapy-Related Anxiety
  • Pediatric Cancer

Keywords

  • Pediatric Cancer
  • Anxiety
  • Chemotherapy
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Asmaa Rashad is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Children diagnosed with cancer receiving active chemotherapy cycles.

Age range between 6 and 10 years at the time of enrollment.

Ability of the child to understand and interact with the storybook content (verbally or non-verbally).

Provision of written by a parent or legal guardian, along with verbal child assent.

Baseline Hospital Anxiety Scale (HAS) assessment completed prior to intervention start.

Exclusion Criteria Children with severe cognitive impairment, advanced neurodevelopmental disorders, or sensory deficits (e.g., severe uncorrected hearing or visual impairment) that impede participation in story-reading sessions.

Children in critical medical condition or receiving end-of-life/palliative care at the time of screening.

Previous exposure to formal structured therapeutic storybook interventions prior to the study.

Inability or unwillingness of the parent/guardian to provide informed consent.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Therapeutic Storybook Series + Routine Care

    participants receive the structured therapeutic storybook series ("Adam's Journey in the Kingdom of the Body") delivered in four individual sessions (20-30 minutes each, twice weekly over a two-week period) alongside routine hospital care.

    Behavioral: therapeutic Storybook Series ("Adam's Journey in the Kingdom of the Body"

  • No intervention
    Routine Care Only

    Control Group (Routine Care Only)

Interventions

  • Behavioraltherapeutic Storybook Series ("Adam's Journey in the Kingdom of the Body"

    A structured, multi-session psychological and educational intervention comprising four custom-written, illustrated therapeutic storybooks ("Adam's Journey in the Kingdom of the Body"). Each session is delivered individually to pediatric oncology patients by a trained nurse researcher in a dedicated, quiet hospital setting. The intervention consists of four 20-to-30-minute sessions conducted twice weekly over a 2-week period alongside routine oncology care. The story series integrates cognitive-behavioral techniques, psychological defense mechanisms, and post-traumatic growth principles using three structured narrative layers (adventure story, parent/metaphor layer, and targeted therapeutic goal). The stories specifically address pediatric chemotherapy procedures, fear of side effects, emotional processing, and coping strategies tailored for children aged 6-10 years.

06

What researchers measure

Primary outcomes

  1. Change in Hospital Anxiety Scale (HAS) Score

    Assessment of anxiety levels in pediatric oncology patients using the validated Hospital Anxiety Scale (HAS). Scores range from 0 to 20, with higher scores indicating higher levels of psychological anxiety and distress.

    Time frame: Baseline (1 day prior to commencing scheduled chemotherapy) and Post-intervention (within 24 hours after completion of the 2-week storybook series).

Secondary outcomes

  1. Intervention Satisfaction Score

    Evaluation of child and parent satisfaction, acceptability, and perceived usefulness of the therapeutic storybook series using a structured post-intervention feedback questionnaire. Higher scores indicate greater satisfaction with the intervention experience.

    Time frame: Post-intervention (within 24 hours after completion of the 2-week intervention).

  2. Behavioral and Emotional Coping Response

    Assessment of changes in child behavioral distress and self-reported coping responses during routine chemotherapy procedures.

    Time frame: Baseline (1 day prior to chemotherapy) and Post-intervention (within 24 hours after completion of the 2-week intervention).

07

Study locations

1 site
  • Different hospitals
    Multiple Locations, Egypt
08

References and documents

Publications

  • Landier, W., & Tse, A. M. (2010). Use of nonpharmacologic interventions for chemotherapy-induced nausea and vomiting in children. Journal of Pediatric Oncology Nursing, 27(6), 346-356.
  • Mutlu, B., & Balcı, S. (2015). Effects of therapeutic stories on anxiety levels of children receiving chemotherapy: A randomized controlled trial. Journal of Pediatric Nursing, 30(6), e119-e127.
  • Spielberger, C. D. (1973). State-Trait Anxiety Inventory for Children (STAIC): Manual. Consulting Psychologists Press. (Standard reference for pediatric clinical anxiety measurement tools).

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) including baseline demographic variables, clinical characteristics, and pre- and post-intervention scores for the primary outcome measure (Hospital Anxiety Scale - HAS) and secondary outcome measures (satisfaction and coping responses) will be shared. In addition to the raw de-identified dataset, key supporting documents will be made available, including the full Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), and the therapeutic storybook intervention module outline ("Adam's Journey in the Kingdom of the Body"). Data will be shared upon reasonable request from qualified academic or clinical researchers after approval of a formal proposal

Supporting information: Study protocol

Time frame: de-identified individual participant data (IPD) and supporting study documentation (Study Protocol, Statistical Analysis Plan, and Informed Consent Form) will become available within 6 months following main manuscript publication and will remain accessible to qualified researchers for a period of 5 years from the initial release date.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for May 2027, 5 months after the start.

Of 1,986 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 5 months is below that.

Counting every sponsor, half of 2,061 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 13, 2026
StartActual
Nov 3, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936318
Lead sponsor
Asmaa Rashad
Responsible party
Asmaa Rashad (msc.Assistant lecturer, Delta University for Science and Technology) — Sponsor-investigator
First posted
Nov 13, 2026
Start date
Nov 3, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion